Lidaltrin

Quinapril, the active ingredient in Lidaltrin, is an Angiotensin‑Converting Enzyme (ACE) inhibitor presented as an oral dosage form for systemic use. It is indicated for the management of hypertension and for treatment of congestive heart failure in adult patients, helping to lower blood pressure and improve cardiac function.

GNH USA supplies Lidaltrin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers. Lidaltrin is manufactured under EU GMP guidelines and distributed through GNH USA's global logistics network.

Quinapril, an ACE inhibitor, is used to manage conditions related to the renin‑angiotensin system.

Hypertension: reduces elevated blood pressure, decreasing risk of cardiovascular events. Congestive heart failure: improves symptoms and reduces workload on the heart. Left ventricular dysfunction: helps to prevent progression of cardiac remodeling.

Quinapril may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Cough - Dizziness or light‑headedness - Headache - Fatigue - Hypotension, especially after the first dose - Altered taste perception

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue, or throat) - Severe neutropenia or leukopenia - Hepatic dysfunction (elevated liver enzymes) - Acute renal impairment or worsening of existing kidney disease - Anaphylactic reactions

When prescribing quinapril, clinicians should consider several precautionary measures.

Monitor blood pressure: check regularly to avoid symptomatic hypotension. Assess renal function: evaluate serum creatinine and electrolytes before initiation and periodically during therapy. Check potassium levels: hyperkalaemia risk is increased when combined with potassium‑sparing agents. Avoid use in patients with a history of angioedema: risk of recurrence is heightened. Pregnancy: use only if clearly needed, as safety has not been established. Store at ambient temperature: keep in the original container, protect from moisture and light.

Quinapril can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined renin‑angiotensin blockade raises risk of renal impairment. - Potassium‑sparing diuretics or potassium supplements: may cause dangerous hyperkalaemia. - NSAIDs: can blunt antihypertensive effect and worsen renal function. - Lithium: ACE inhibition raises lithium levels, increasing toxicity risk.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance hypotensive effect; monitor blood pressure. - Beta‑blockers: additive blood pressure lowering; monitor heart rate and hemodynamics.